摘要
目的:研究前列腺氩氦刀冷冻消融术作为转移性前列腺癌局部治疗的疗效和安全性。方法:回顾性分析2011年4月至2014年4月我科收治的48例行氩氦刀冷冻消融术作为局部治疗的前列腺癌伴骨转移患者的临床资料。结果:患者均手术顺利,无并发症发生,平均手术时间(90.5±20.2)min。患者均获得随访1年,1年内无死亡病例。前列腺特异性抗原(PSA)首次降低至0.2 ng/m L以下的中位时间为7个月,95%可信区间(6.17,7.83)。Cox比例风险回归模型分析提示:术前前列腺体积、PSA水平是影响PSA首次降低至0.2 ng/m L时间的有效变量。结论:前列腺氩氦刀冷冻消融术能有效治疗转移性前列腺癌的局部病灶。术前前列腺体积和PSA水平是影响PSA首次降至0.2 ng/m L以下时间的有效因素。
Objective To evaluate the therapeutic effect and safety of argon-helium cryoablation for prostate cancer with bone metastasis. Methods The clinical data on 48 proststate cancer patients with bone metastasis who had undergone argon-helium cryoablation were retrospectively analyzed. Results All the patients received the procedure successfully without complications. The average operation time was （90.5± 20.2） min. All the patients were followed up for one year without death. Median time of PSA descending below 0.2 ng/mL for the first time was 7 months [95% cofidence interval： （6.17, 7.83）]. Cox proportion hazards regression model suggested preoperative prostate volume and prostate specific antigen level were the effective variables to influence the time of PSA declining below 0.2 ng/mL for the first time. Conclusions Argon-helium cryoablation can effectively remove local lesions of prostate cancer with bone metastasis. Preoperative prostate volume and prostate specific antigen level are the effective factors to influence the time of PSA decreasing below 0.2 ng/mL for the first time.
出处
《实用医学杂志》
CAS
北大核心
2015年第21期3545-3547,共3页
The Journal of Practical Medicine
关键词
前列腺肿瘤
骨转移
冷冻消融术
Prostate neoplasms
Bone metastasis
Cryoablation
